Business Description
Spero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US84833T1034
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 13.77 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.22 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.76 | |||||
Beneish M-Score | 22.69 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 433.9 | |||||
3-Year FCF Growth Rate | 45.5 | |||||
3-Year Book Growth Rate | -23.5 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.4 | |||||
9-Day RSI | 26.96 | |||||
14-Day RSI | 33.74 | |||||
6-1 Month Momentum % | 53.1 | |||||
12-1 Month Momentum % | -1.14 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.53 | |||||
Quick Ratio | 3.53 | |||||
Cash Ratio | 2.05 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.9 | |||||
Shareholder Yield % | 1.19 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 27.69 | |||||
Net Margin % | 23.58 | |||||
FCF Margin % | -34.11 | |||||
ROE % | 32.02 | |||||
ROA % | 18.22 | |||||
ROIC % | 64.34 | |||||
ROC (Joel Greenblatt) % | 528.5 | |||||
ROCE % | 25.35 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 3.3 | |||||
PE Ratio without NRI | 2.78 | |||||
PS Ratio | 0.71 | |||||
PB Ratio | 0.7 | |||||
Price-to-Tangible-Book | 0.7 | |||||
EV-to-EBIT | 0.33 | |||||
EV-to-EBITDA | 0.33 | |||||
EV-to-Revenue | 0.09 | |||||
EV-to-Forward-Revenue | 0.17 | |||||
EV-to-FCF | -0.26 | |||||
Price-to-Graham-Number | 0.3 | |||||
Price-to-Net-Current-Asset-Value | 1.35 | |||||
Price-to-Net-Cash | 71 | |||||
Earnings Yield (Greenblatt) % | 303.03 | |||||
FCF Yield % | -43.12 |